How Abivax (ABVX) Turned Heads With Whopping 1700% Surge in 2025

We recently published 10 Market Stars Behind Millionaire-Making in 2025. ABIVAX Societe Anonyme (NASDAQ:ABVX) is last year’s top performer.

Abivax skyrocketed by 1,742.28 percent in 2025, as investor sentiment was primarily bolstered by a series of upbeat analyst outlooks, strong clinical trial results, and its official inclusion in Nasdaq’s biotechnology index.

ABIVAX Societe Anonyme (NASDAQ:ABVX) officially joined the Nasdaq biotechnology index (NBI) on December 22, designed to track the performance of a set of biotechnology and pharmaceutical companies listed on the Nasdaq.5 Countries With Highest Pharmaceutical Spend Per Capita

Companies belonging to the index must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria.

“Our inclusion in the Nasdaq Biotechnology Index marks a significant milestone for Abivax. It highlights the meaningful progress we’ve made as a company, particularly in advancing obefazimod through the successful Phase 3 ABTECT Induction trials for ulcerative colitis and reflects the increased visibility and perception of Abivax within the global biotechnology community,” said ABIVAX Societe Anonyme (NASDAQ:ABVX) Chief Finance Officer Didier Blondel.

Meanwhile, ABIVAX Societe Anonyme (NASDAQ:ABVX) also earned “buy” recommendations from a series of investment companies, namely Guggenheim Securities, Truist Financial, and Citizens, alongside price targets of $175, $140, and $131, respectively, reflecting upbeat analyst outlooks.

The coverage followed strong results from the phase 3 trial to test the efficacy of obefazimod in patients with moderate to severe ulcerative colitis, where enrolled patients who took 50 mg of obefazimod saw a significant improvement in their conditions and their colon lining, suggesting real disease healing.

While we acknowledge the risk and potential of ABVX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABVX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.